Utama › Penyakit Crohn › Louisiana
Kajian klinikal Penyakit Crohn di Louisiana
11 kajian untuk Penyakit Crohn sedang mencari peserta di lokasi di Louisiana.
Bandar di Louisiana
- Lafayette7 kajian
- Metairie5 kajian
- Shreveport3 kajian
- Monroe3 kajian
- New Orleans3 kajian
- Baton Rouge3 kajian
Teks kajian rasmi (Bahasa Inggeris)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
Mengambil pesertaFasa 4
Umur 18 hingga 80 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06581328A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
- Delta Research Partners, LLC, West Monroe
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
Mengambil pesertaFasa 3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma-Site Number: 8400034, Houma
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 16 hingga 80 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Baton Rouge-Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville-Site Number: 8400128, Mandeville
- GI Alliance - Metairie-Site Number: 8400124, Metairie
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 16 hingga 80 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Tandem Clinical Research, Houma
Mengambil pesertaFasa 2
Umur 18 hingga 85 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06226883A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance, Metairie
- Tulane University, New Orleans
Mengambil pesertaFasa 4
Umur 18 hingga 70 · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Clinic of Acadiana, Lafayette
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07577843A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 12 Mac 2026 · NCT07113522Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.